江中药业(600750.SH)：晋城海斯盐酸奥洛他定片获得药品注册批件
格隆汇 · 06/13/2022 08:14
Share
Listen to the news
江中药业(600750.SH)：晋城海斯盐酸奥洛他定片获得药品注册批件
格隆汇6月13日丨江中药业(600750.SH)公布，近日，江中药业股份有限公司控股子公司晋城海斯制药有限公司(简称“晋城海斯”)收到了国家药品监督管理局核准签发的盐酸奥洛他定片(5mg)(以下简称“该药品”)《药品注册证书》，批准该药品生产。
盐酸奥洛他定片是一种抗过敏药物，适用于过敏性鼻炎、荨麻疹、瘙痒性皮肤病(湿疹、皮炎、痒疹、皮肤瘙痒症、寻常性银屑病、渗出性多形红斑)。
晋城海斯自2020年12月31日向国家药监局提交该药品的上市申请，于2021年2月5日获得受理通知书，并于2022年05月31日获得国家药监局批准。截至公告日，晋城海斯针对该药品研发投入约为人民币400万元(未经审计)。
根据PDB样本医院数据网显示，盐酸奥洛他定片2019年、2020年、2021年在中国城市公立医院终端市场销售额分别为1.6亿元、2.14亿元、2.3亿元。
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
Share your ideas here…
All Comments
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2025 Webull. All Rights Reserved